Viktor V. Maleyev

Viktor V. Maleyev

Auto-generated profile, based on publicly available information

Viktor V. Maleyev

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
Mikhail Yurievich ShchelkanovMikhail Yurievich Shchelkanov
Mikhail Yurievich Shchelkanov
APA. Yu. Popova
A. Yu. Popova
VDVladimir George Dedkov
Vladimir George Dedkov
VAVasily G Akimkin
Vasily G Akimkin
VMV. V. Maleyev
V. V. Maleyev
An epidemic of COVID-19 (Coronavirus disease 2019) etiologically associated with the SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) that occurred at the turn of 2019–2020 firstly in Wuhan (Hubei province of China) and then spread to many countries around the world rose a new wave of interest to coronaviruses. The first coronaviruses – members of the Coronaviridae family belonging to the order Nidovirales — were discovered in the first half of the last century. The first human coronavirus, HCoV-B814, was isolated in 1965 that was not preserved in available virological collections. Over the last time, old-fashioned names and terms have been overlapped. By the beginning of the XXI century coronaviruses posed a serious veterinary problem but it was believed that epidemic coronaviruses were not among highly dangerous viruses. Scientific community had to revise such views first in 2002 when SARS-CoV (Severe acute respiratory syndrome-related coronavirus) was transferred to human population in the Southeast Asia from bats, and then in 2012 when natural foci of the MERS-CoV (Middle East respiratory syndrome-related coronavirus) were found on the territory of the Arabian Peninsula. Due to an increased interest in coronaviruses, a large number of new Coronaviridae members was discovered in the first two decades of the XXI century, which required to revise its taxonomic structure several times. This review is aimed at outlining a history of investigating coronaviruses and their current classification that was shaped in early 2020 in accordance to the last recommendations of the International Committee on Taxonomy of Viruses.

28 December 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
АKАлексей Kravchenko
Алексей Kravchenko
VMViktor V. Maleyev
Viktor V. Maleyev
The article presents an overview of clinical recommendations for currant antiretroviral therapy. Currently, the current preferred first-line antiretroviral therapy regimens are combinations of 2 or 3 antiretroviral drugs (ARVs) in one tablet with a frequency of administration 1 time per day and, as a rule, include drugs of the 2nd generation (integrase inhibitors or non-nucleoside reverse transcriptase inhibitors). These schemes have high efficiency and a good genetic barrier in the development of HIV resistance mutations. HIV protease inhibitors are used as alternative regimens. Schemes with the least number and spectrum of side effects, no effect on metabolic processes and minimal drug interactions have advantages. Switching patients to injectable therapy regimens with a frequency of administration of drugs once every 2 months can significantly improve the quality of life of patients and, accordingly, adherence to their treatment. The development and introduction of new classes of ARVs into clinical practice ensures the suppression of HIV replication in most patients with HIV strains resistant to drugs of the main groups of ARVs (nucleoside/nucleotide reverse transcriptase

1 January 2025 in Infekcionnye bolezni
Verified
Journal Article
Closed access
IAIzhevsk Izhevsk State Medical Academy
Izhevsk Izhevsk State Medical Academy
TKT.M. Kamenshchikova
T.M. Kamenshchikova
VMV.A. Malov
V.A. Malov
DSD.S. Sarksyan
D.S. Sarksyan
OMO.V. Malinin
O.V. Malinin
VMV.V. Maleev
V.V. Maleev
The incidence of human pasteurellosis is low, but severe lung damage or septicaemia with fatal outcome is possible in the presence of immune deficiency. Information on the etiology, epidemiology, clinical course, diagnosis and etiotropic therapy of the disease caused by Pasteurella multocida is presented. In addition, the article presents a clinical case of primary-septic form of pasteurellosis with lethal outcome, developed in an elderly patient without primary focus and concomitant immunodeficiency. Data on pathological and anatomical changes in severe course of pasteurellosis are presented separately. Key words: lethal outcome, treatment, pasteurellosis, pathomorphology of sepsis, septicaemia, septic shock

26 December 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VMValeri A. Malov
Valeri A. Malov
VPViktoriia B. Poluektova
Viktoriia B. Poluektova
ASAleksandr P. Shakotko
Aleksandr P. Shakotko
OTOleg A. Tishkevich
Oleg A. Tishkevich
VMViktor V. Maleyev
Viktor V. Maleyev
NMNatalya V. Maloletneva
Natalya V. Maloletneva
The article describes a clinical case of an unfavorable course of pasteurellosis in a patient with liver cirrhosis. Possible variants of the clinical course, clinical and epidemiological data, on the basis of which pasteurellosis can be suspected, modern recommendations for antibiotic therapy are considered.

1 January 2026 in Infekcionnye bolezni
Verified
Journal Article
Closed access
MDM.V. Dudarev
M.V. Dudarev
NYN.R. Yamoldinov
N.R. Yamoldinov
DSD.S. Sarksyan
D.S. Sarksyan
ASA.E. Shklyaev
A.E. Shklyaev
EIE.N. Ievlev
E.N. Ievlev
VMV.V. Maleev
V.V. Maleev
This study demonstrated the possibility of nearly complete recovery in a patient 2.5 years after an extremely severe course of coronavirus infection with 100% lung involvement and prolonged extracorporeal membrane oxygenation. Nevertheless, the presence of subclinical signs of pulmonary fibrosis according to spiral computed tomography and body plethysmography, as well as signs of post-infarction cardiosclerosis and chronic heart failure according to laboratory tests and electrocardiography, dictates the need for long-term dynamic health monitoring for this particular patient and for convalescents of coronavirus infection in general. Key words: COVID-19, cardiorenal syndrome, post-COVID syndrome, pulmonary fibrosis, chronic heart failure

1 January 2025 in Infekcionnye bolezni
Verified
Journal Article
Closed access
AKA.N. Khasanova
A.N. Khasanova
GKG.M. Khasanova
G.M. Khasanova
VMV.V. Maleev
V.V. Maleev
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
VVV.A. Vorobev
V.A. Vorobev
GWGuoqing Wang
Guoqing Wang
Objective. To evaluate the prognostic potential of exosomal microRNAs (miR-146a-5p, miR-155-5p, miR-126-3p, miR-218-5p, miR-410-3p, miR-503-5p, miR-29a-3p) depending on the severity of HFRS. Patients and methods. We examined 288 patients at the Republican Clinical Infectious Diseases Hospital in Ufa in 2023–2025 with a diagnosis of HFRS: moderate severity (n = 105), severe (n = 99), and severe with complications (n = 84). Blood samples for molecular genetic analysis were taken during the febrile, oliguric, and convalescent periods of HPS. Total RNA was isolated using the exoRNeasy Midi Kit (Qiagen, Germany). Quantitative real-time PCR (qRT-PCR) was performed using the miRCURY LNA SYBR Green PCR Kit (Qiagen, Germany) and the LightCycler96 real-time PCR product detection system (Roche, Switzerland). Results. When comparing groups of patients with varying severity, distinct differences were found in the levels of exosomal microRNAs miR-146a-5p and miR-155-5p. In patients with severe disease with complications, the level of miR-146a-5p was higher than in patients with moderate disease (FC = 2.70, p = 0.0022, q = 0.007). For miR-155-5p, the increase was FC = 1.86 in severe cases (p = 0.049, q = 0.11 – trend) and FC = 1.98 in severe cases with complications (p = 0.001, q = 0.009). For miR‑503-5p, a weak tendency toward a decrease was identified in severe forms (–25–30% of the medium to severe form, p = 0.08), which may have pathogenetic significance. Significant correlations were found between miR-155-5p/miR-503-5p and clinical and laboratory parameters: creatinine, C-reactive protein, and duration of fever. Conclusion. MicroRNA-146a-5p and microRNA-155-5p can be considered as early prognostic biomarkers of HFRS severity. Our findings expand the understanding of the role of microRNAs in the pathogenesis of HFRS and confirm the need for further research to develop microRNA-based prognostic tests and targeted interventions. Key words: hemorrhagic fever with renal syndrome, microRNA severity of HFRS